Analysis
USA
Racine
Analysis
USA
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur l'opéra

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Le cluster tolerability - tolterodine

Terms

3tolerability
3tolterodine
3release
3oxybutynin
4extended
2bladder
2overactive
2formulations

Associations

Freq.WeightAssociation
31.000tolerability - tolterodine
31.000release - tolterodine
31.000release - tolerability
31.000oxybutynin - tolterodine
31.000oxybutynin - tolerability
31.000oxybutynin - release
30.866extended - tolterodine
30.866extended - tolerability
30.866extended - release
30.866extended - oxybutynin
21.000bladder - overactive
20.816overactive - tolterodine
20.816overactive - tolerability
20.816overactive - release
20.816overactive - oxybutynin
20.816formulations - tolterodine
20.816formulations - tolerability
20.816formulations - release
20.816formulations - oxybutynin
20.816bladder - tolterodine
20.816bladder - tolerability
20.816bladder - release
20.816bladder - oxybutynin
20.707extended - overactive
20.707extended - formulations
20.707bladder - extended
Documents par ordre de pertinence
000318 (2003) Ananias C. Diokno [États-Unis] ; Rodney A. Appell [États-Unis] ; Peter K. Sand [États-Unis] ; Roger R. Dmochowski [États-Unis] ; Bernard M. Gburek [États-Unis] ; Ira W. Klimberg [États-Unis] ; Sherron H. Kell [États-Unis]Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial
000275 (2006) Rodney U. Anderson [États-Unis] ; Scott Macdiarmid ; Sherron Kell ; James H. Barada ; Scott Serels ; Roger P. GoldbergEffectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.
000294 (2005) Franklin M. Chu [États-Unis] ; Roger R. Dmochowski [États-Unis] ; Daniel J. Lama [États-Unis] ; Rodney U. Anderson [États-Unis] ; Peter K. Sand [États-Unis] ; Kelly MolpusExtended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles : A subanalysis of data from the OPERA trial. Discussion
000142 (2010) Elizabeth Levy Paluck [États-Unis]Is it better not to talk? Group polarization, extended contact, and perspective taking in Eastern Democratic Republic of Congo.
Wicri

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Jan 4 23:09:23 2024